Effects of YM155 on survivin levels and viability in neuroblastoma cells with acquired drug resistance

Survivin and Tumorigenesis: Molecular Mechanisms and Therapeutic Strategies

(2016) Xun Chen et al.   Journal of Cancer

YM155 potently kills acute lymphoblastic leukemia cells through activation of the DNA damage pathway

(2015) Bill H Chang et al.   Journal of Hematology & Oncology

BIRC5/Survivin as a target for glycolysis inhibition in high-stage neuroblastoma

(2015) J Hagenbuchner et al.   ONCOGENE

Enzastaurin inhibits ABCB1-mediated drug efflux independently of effects on protein kinase C signalling and the cellular p53 status

(2015) Martin Michaelis et al.   Oncotarget

YM155 potently triggers cell death in breast cancer cells through an autophagy-NF-kB network

(2015) Eloïse Véquaud et al.   Oncotarget

Identification of flubendazole as potential anti-neuroblastoma compound in a large cell line screen

(2015) Martin Michaelis et al.   Scientific Reports

Preclinical efficacy of sepantronium bromide (YM155) in multiple myeloma is conferred by down regulation of Mcl-1

(2015) Verena Wagner et al.   Oncotarget

Anticancer Effects of the Nitric Oxide-Modified Saquinavir Derivative Saquinavir-NO against Multidrug-Resistant Cancer Cells

(2015) Florian Rothweiler et al.   NEOPLASIA

YM155 down-regulates survivin and XIAP, modulates autophagy and induces autophagy-dependent DNA damage in breast cancer cells

(2014) S M Cheng et al.   BRITISH JOURNAL OF PHARMACOLOGY

miR-542-3p exerts tumor suppressive functions in neuroblastoma by downregulating Survivin

(2014) Kristina Althoff et al.   INTERNATIONAL JOURNAL OF CANCER

Small-molecule survivin inhibitor YM155 enhances radiosensitization in esophageal squamous cell carcinoma by the abrogation of G2 checkpoint and suppression of homologous recombination repair

(2014) Qin Qin et al.   Journal of Hematology & Oncology

The solute carrier SLC35F2 enables YM155-mediated DNA damage toxicity

(2014) Georg E Winter et al.   Nature Chemical Biology

Pharmacologic activation of wild-type p53 by nutlin therapy in childhood cancer

(2013) Tom Van Maerken et al.   CANCER LETTERS

YM155 sensitizes ovarian cancer cells to cisplatin inducing apoptosis and tumor regression

(2013) Roser Mir et al.   GYNECOLOGIC ONCOLOGY

Current and Future Strategies for Relapsed Neuroblastoma

(2013) Daniel A. Morgenstern et al.   JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY

Bortezomib antagonizes microtubule-interfering drug-induced apoptosis by inhibiting G2/M transition and MCL-1 degradation

(2013) F Rapino et al.   Cell Death & Disease

The “survivin suppressants” NSC 80467 and YM155 induce a DNA damage response

(2012) Trevor G. Glaros et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

VarScan 2: Somatic mutation and copy number alteration discovery in cancer by exome sequencing

(2012) D. C. Koboldt et al.   GENOME RESEARCH

Population pharmacokinetic modeling of Sepantronium bromide (YM155), a small molecule survivin suppressant, in patients with non-small cell lung cancer, hormone refractory prostate cancer, or unresectable stage III or IV melanoma

(2012) Yumiko Aoyama et al.   INVESTIGATIONAL NEW DRUGS

Radiosynthesis, biodistribution and imaging of [11C]YM155, a novel survivin suppressant, in a human prostate tumor-xenograft mouse model

(2012) Yoshihiro Murakami et al.   NUCLEAR MEDICINE AND BIOLOGY

Children's Oncology Group's 2013 blueprint for research: Neuroblastoma

(2012) Julie R. Park et al.   PEDIATRIC BLOOD & CANCER

Mcl-1 downregulation by YM155 contributes to its synergistic anti-tumor activities with ABT-263

(2011) Haikuo Tang et al.   BIOCHEMICAL PHARMACOLOGY

Antitumor Activity of YM155, a Selective Small-Molecule Survivin Suppressant, Alone and in Combination with Docetaxel in Human Malignant Melanoma Models

(2011) Kentaro Yamanaka et al.   CLINICAL CANCER RESEARCH

Targeting survivin in cancer: the cell-signalling perspective

(2011) Jagat R. Kanwar et al.   DRUG DISCOVERY TODAY

Utility of P-Glycoprotein and Organic Cation Transporter 1 Double-Transfected LLC-PK1 Cells for Studying the Interaction of YM155 Monobromide, Novel Small-Molecule Survivin Suppressant, with P-Glycoprotein

(2011) M. Iwai et al.   DRUG METABOLISM AND DISPOSITION

Knockdown of survivin (BIRC5) causes apoptosis in neuroblastoma via mitotic catastrophe

(2011) Fieke Lamers et al.   ENDOCRINE-RELATED CANCER

Targeted BIRC5 silencing using YM155 causes cell death in neuroblastoma cells with low ABCB1 expression

(2011) Fieke Lamers et al.   EUROPEAN JOURNAL OF CANCER

Targeting survivin and p53 in pediatric acute lymphoblastic leukemia

(2011) J W Tyner et al.   LEUKEMIA

Adaptation of cancer cells from different entities to the MDM2 inhibitor nutlin-3 results in the emergence of p53-mutated multi-drug-resistant cancer cells

(2011) M Michaelis et al.   Cell Death & Disease

Broad spectrum and potent antitumor activities of YM155, a novel small-molecule survivin suppressant, in a wide variety of human cancer cell lines and xenograft models

(2010) Takahito Nakahara et al.   CANCER SCIENCE

Radiation-Induced Survivin Nuclear Accumulation is Linked to DNA Damage Repair

(2010) Gianni Capalbo et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

The Sequence Alignment/Map format and SAMtools

(2009) H. Li et al.   BIOINFORMATICS

Reversal of P-glycoprotein-Mediated Multidrug Resistance by the Murine Double Minute 2 Antagonist Nutlin-3

(2009) M. Michaelis et al.   CANCER RESEARCH

Phase I Study of YM155, a Novel Survivin Suppressant, in Patients with Advanced Solid Tumors

(2009) T. Satoh et al.   CLINICAL CANCER RESEARCH

Radiosensitizing Effect of YM155, a Novel Small-Molecule Survivin Suppressant, in Non-Small Cell Lung Cancer Cell Lines

(2008) T. Iwasa et al.   CLINICAL CANCER RESEARCH

Phase I and Pharmacokinetic Study of YM155, a Small-Molecule Inhibitor of Survivin

(2008) Anthony W. Tolcher et al.   JOURNAL OF CLINICAL ONCOLOGY

A Multicolor Panel of Novel Lentiviral “Gene Ontology” (LeGO) Vectors for Functional Gene Analysis

(2008) Kristoffer Weber et al.   MOLECULAR THERAPY